Barinthus Biotherapeutics merger closes, shareholders receive 0.111 Topco shares per share

• Topco completed its acquisition of Barinthus Biotherapeutics, taking all issued and to-be-issued ordinary shares at the scheme effective time.
• Each Barinthus share, including those underlying ADSs, was exchanged for 0.111 shares of Topco common stock.
• Fractional share entitlements will be cashed out under the scheme and merger agreement terms.
• The ADS deposit agreement dated April 29, 2021, with Bank of New York Mellon was terminated upon effectiveness.
• Outstanding equity options were converted into Topco options on substantially the same vesting and exercise terms.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Barinthus Biotherapeutics plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-106183), on September 09, 2026, and is solely responsible for the information contained therein.